Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$128.06 USD

128.06
183,872

+0.31 (0.24%)

Updated Aug 8, 2025 11:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Celgene (CELG) Submits NDA for MS Drug to FDA for Review

by Zacks Equity Research

Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

Zacks Equity Research

AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan

by Zacks Equity Research

AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.

Zacks Equity Research

Biogen Stock Crashes on Termination of Alzheimer's Studies

by Zacks Equity Research

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

Zacks Equity Research

Company News For Mar 22, 2019

by Zacks Equity Research

Companies in the news are: BIIB, CAG, DRI, WSM

Mark Vickery headshot

Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets

by Mark Vickery

Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.

Zacks Equity Research

Initial Jobless Claims Decline

by Zacks Equity Research

Initial Jobless Claims Decline

Mark Vickery headshot

Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets

by Mark Vickery

Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.

Zacks Equity Research

Alkermes Focuses on Pipeline, Depends on Partners for Funds

by Zacks Equity Research

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

Zacks Equity Research

PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

Zacks Equity Research

Celgene (CELG) Submits Application for MS Drug in Europe

by Zacks Equity Research

Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

Mark Vickery headshot

Top Stock Reports for Visa, Honeywell & Biogen

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Honeywell (HON) and Biogen (BIIB).

Zacks Equity Research

Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

by Zacks Equity Research

Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

Zacks Equity Research

Biogen to Acquire Gene-Therapy Company Nightstar for $800M

by Zacks Equity Research

Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.

Zacks Equity Research

Company News For Mar 5, 2019

by Zacks Equity Research

Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

Zacks Equity Research

AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab

by Zacks Equity Research

AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.

Zacks Equity Research

Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA

by Zacks Equity Research

The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.

Zacks Equity Research

Novartis In-Licenses Rights to Heart Candidate From Ionis

by Zacks Equity Research

Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.

Zacks Equity Research

AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review

by Zacks Equity Research

AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.

Zacks Equity Research

Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

Sanghamitra Saha headshot

Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

by Sanghamitra Saha

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T

Mark Vickery headshot

Top Research Reports for Visa, Charter Communications & Biogen

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Charter Communications (CHTR) and Biogen (BIIB).

Zacks Equity Research

Alkermes Sinks as FDA Refuses to Approve Depression Drug

by Zacks Equity Research

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

Zacks Equity Research

Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.